"Drug Curry Jun" large varieties of diabetes first imitation evaluation, antibacterial large varieties approved, anesthesia field a number of declarations, Novartis, Howson, a magenta ...

Read: The Latest! Domestic and foreign drug review dynamics! This week's look: 1. International drug dynamics.
2. Engree Net was approved for the first time in China, and Howson deepened the layout of the diabetes product line.
3. Large varieties of antimicrobials were approved, and the market position in the field of magenta anti-infection was further enhanced.
4. Shumore sodium, grounderos and other generic drugs listed applications were accepted.
this issue (July 31 to August 7) a number of international and domestic products were approved for listing.
internationally, heavy-duty drugs are frequently approved: Novartis Cosentyx ® (CucciYusmatis) the European Union has been approved for first-line treatment of children's psoriasis; Hepcudex EU approved for hepatitis Dinos; and Roche tyrosine kinase inhibitor Rozlytrek (entrectinib) has been approved for conditional listing.
FDA approves a new drug application for Thesen's NMDA receptor nasal spray Spravato (esketamine) CIII supplementation drug, in conjunction with oral antidepressants to treat depressive symptoms in adult patients with depression (MDD) accompanied by acute suicidal thoughts or behavior, Spravato is the only FDA-approved drug to show reducing depressive symptoms within 24 hours.
in the country, a number of imitation, imported products approved for listing, more dynamics are as follows: domestic review and approval, new dynamics this week CDE has 17 acceptance numbers (14 varieties) reported production status updates, including hydrochloric acid Klinmycin capsules and Engler net and other large varieties were approved of the attention, more dynamics are as follows: Engrenet net domestic first imitation approved, Haussen deepening layout of diabetes product line recently, Howson Pharmaceuticals ngre net film was approved for the first domestic
the drug is suitable for improving blood sugar control in patients with type 2 diabetes in conjunction with diet control and exercise.
Ngrenet is a sodium-glucose co-transporter-2 (SGLT-2) inhibitor class that has a unique insulin-free sugar-reducing mechanism, which removes sugar directly from the urine by reducing the reabsorption of glucose in the kidneys.
With net global sales of $3.354 billion, Engre's net global sales are among the world's best-selling drugs, TOP 40, according to Bollinger Ingham and Lilly's 2019 financial results.
drug data show that Howson later submitted applications for the listing of Theure net generics, including Collum Pharmaceuticals, Zhengda Qing, Jiangsu Wanbang and Jiangsu Osaikang, and other enterprises, followed by fierce competition.
a large variety of antimicrobial drugs in Guangzhou, clineacid Klinmycin capsule approved hydrochloric acid Klinmycin capsules are suitable for serious infectioncause of sensitive anaerobic bacteria and serious infections caused by sensitive strains such as streptococcus, pneumococcal and staphylococcus, but only for patients who are allergic to penicillin or patients judged by doctors not to use penicillin.
its applicable population includes adults and children.
hydrochloric acid klinmycin capsules in the domestic has entered the medical insurance Class A, base medicine catalog;
sales of klinmycin in China's public medical institutions terminal has exceeded 3 billion yuan, as the leading enterprise of this variety, related products are mainly hydrochloric acid klinmycin palmate dispersion tablets, hydrochloric acid klinmycin palmacid particles, injection of klinmycin.
obtained the registration certificate of 3 kinds of product regulations of klinmycin capsule hydrochloric acid, further enriching the company's product category and enhancing the company's competitiveness in the field of anti-infection.
domestic review and approval, new acceptance of this week CDE new report production acceptance number 27, a total of 18 varieties, of which Shumore glucose sodium injection, tirano sodium dispersion tablets received attention, more dynamic see the following table: Shu more glucose sodium patent is about to expire, more than 10 enterprises competing for the first imitation, Zhejiang Xianyuska than Pharmaceutical Co., Ltd. Shu more glucosaride injection application has been accepted.
sodium sodium sodium sutrose injection is the world's first selective sagging antagonistic agent for reversing neuromuscular blockers, suitable for antagonic ammonium bromine or viku bromine-induced neuromuscular blockers.
Shugen sodium sodium injection research developed by Mercadong Company, in July 2008 for the first time approved in the European Union, has been registered in the United States and Japan in several countries, in April 2017 in China approved the listing, 2019 global sales of 7.79 billion yuan.
Shu more glucose sodium injection in the last 5 years the global sales of Su-more sodium glucose original research compound patent will expire on November 23, 2020 (PCT patent), at present, there are 12 domestic enterprises registered to declare generic drugs on the market, a number of domestic large pharmaceutical companies compete for the first imitation, domestic Shumore sodium glucose injection is expected to be approved after rapid import substitution.
Kangchen Pharmaceuticals expanded its product line, Thelaros Dispersal Tablet Listing Application accepted by Tiraros is an oral iron ion chelating agent, effectively improving iron excretion, reducing the content of iron in the body and its pathological deposition in various organs;
the original research company of the DeLaros dispersal is Novartis of Switzerland, which reported global sales of $975 million in 2019.
last year, the Tiranos spread through national negotiations to enter the latest version of the health care catalog.
pharmaceutical data show that in addition to Kangchen Pharmaceuticals, there are two enterprises - Jiangsu Oseikang Pharmaceutical Co., Ltd. and Dr. Reddy (Wuxi) Pharmaceutical Co., Ltd. of the imitation declaration has entered the drug review center technical review stage, but has not yet been approved.
for Kangchen Pharmaceuticals, whose revenues are almost exclusively supported by a product of "Souling", the company's approval of the listing will undoubtedly bring new profit growth points to the company.
data source: drug intelligence data, enterprise announcements and other network public data sources: drug intelligence network, enterprise announcements and other network public information.